Loading organizations...
§ Private Profile · Houston, TX, USA
Biotech company developing targeted anticancer drugs using a CLYP platform for oncology, focused on ovarian cancer.
Esperance Pharmaceuticals is a Houston, Texas-based biotechnology company that develops targeted anticancer drugs utilizing a proprietary Cationic Lytic Peptide platform to selectively destroy malignant cancer cells. The clinical-stage organization focuses primarily on the broader oncology sector, advancing specialized therapeutic treatments for adult patients with ovarian, prostate, and breast cancers. Its lead drug candidate, EP-100, successfully completed Phase 2 clinical trials for advanced ovarian cancer following a $7.5 million Series B financing round raised in late 2011. To advance its clinical pipeline, the enterprise has collaborated closely with the MD Anderson Cancer Center and secured venture capital backing from prominent institutional investors, including Sanofi, Louisiana Fund I, and Themelios Ventures. Esperance Pharmaceuticals was officially founded in 2006 by Hector Alila, building upon patented technological innovations originating from the LSU AgCenter and the Pennington Biomedical Research Center.
Esperance Pharmaceuticals has raised $7.5M across 1 funding round.
Esperance Pharmaceuticals has raised $7.5M in total across 1 funding round.
Esperance Pharmaceuticals has raised $7.5M in total across 1 funding round.
Esperance Pharmaceuticals's investors include Sanofi, Advantage Capital, Louisiana Fund I, Research Corporation Technologies, Themelios Ventures.
Esperance Pharmaceuticals has raised $7.5M across 1 funding round. Most recently, it raised $7.5M Series B in June 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2011 | $7.5M Series B | Sanofi | Advantage Capital, Louisiana Fund I, Research Corporation Technologies, Themelios Ventures | Announced |